Compare CRNX & MMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNX | MMS |
|---|---|---|
| Founded | 2008 | 1975 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.7B |
| IPO Year | 2018 | 1997 |
| Metric | CRNX | MMS |
|---|---|---|
| Price | $47.18 | $84.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 1 |
| Target Price | $71.00 | ★ $90.00 |
| AVG Volume (30 Days) | ★ 1.4M | 669.4K |
| Earning Date | 11-06-2025 | 11-20-2025 |
| Dividend Yield | N/A | ★ 1.42% |
| EPS Growth | N/A | ★ 10.42 |
| EPS | N/A | ★ 5.51 |
| Revenue | $1,535,000.00 | ★ $5,431,276,000.00 |
| Revenue This Year | $425.31 | $1.71 |
| Revenue Next Year | $943.50 | $4.98 |
| P/E Ratio | ★ N/A | $15.37 |
| Revenue Growth | ★ 47.74 | 2.36 |
| 52 Week Low | $24.10 | $63.77 |
| 52 Week High | $60.34 | $92.50 |
| Indicator | CRNX | MMS |
|---|---|---|
| Relative Strength Index (RSI) | 61.29 | 50.79 |
| Support Level | $44.52 | $85.53 |
| Resistance Level | $48.62 | $87.92 |
| Average True Range (ATR) | 2.00 | 2.43 |
| MACD | 0.29 | 0.32 |
| Stochastic Oscillator | 72.38 | 62.49 |
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
Maximus Inc designs, develops, and delivers programs enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments: U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment, which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.